ENTA: Rega marang dodolan Enanta

Logo korporat perusahaan Enanta Pharmaceuticals, Inc (ENTA)

Enanta Pharmaceuticals (ENTA) generates revenue through royalties from hepatitis treatments and government healthcare support. The price-to-sales valuation reflects volatility driven by sanctions pressure on raw materials and testing barriers. Meanwhile, a robust R&D pipeline and partnerships with industry behemoths provide stability. The current level of 4.90 indicates the asset's real-time market value relative to its actual earnings.

ENTA (Enanta Pharmaceuticals) riwayat Multiplikator P/S saka 04.07.2022 nganti 14.11.2026

Enanta (ENTA) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Bagan bursa enanta.com|ENTA - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Nilai pasar Enanta|ENTA - Nilai Total Perusahaan
- data nilai buku modal saham:
Ekuitas saben Saham Enanta Pharmaceuticals|ENTA - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku enanta.com|ENTA - Aset Agregat Perusahaan
- indikator beban kredit lan likuiditas emiten:
Rasio Utang marang Ekuitas Enanta Pharmaceuticals|ENTA - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Enanta Pharmaceuticals, Inc|ENTA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Enanta|ENTA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Enanta Pharmaceuticals|Rasio likuiditas kritis enanta.com
- indikator pendapatan resik lan kelipatan nilai:
ENTA - Bathi resik|Penghasilan resik sing dikarepake Enanta Pharmaceuticals|ENTA - Pangali P/E|Pangali Forward P/E Enanta Pharmaceuticals Inc.|ENTA - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Enanta|ENTA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Enanta Pharmaceuticals|ENTA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan enanta.com|ENTA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Enanta Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
ENTA - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan enanta.com|ENTA - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Enanta
Analisis umum perusahaan:ENTA enanta.com
Produk sing diprodhuksi Enanta Pharmaceuticals Inc.

The P/S ratio measures the market value of a business relative to its sales volume, allowing for the determination of an asset's overvaluation depending on the phase of the economic cycle. By analyzing the price-to-sales ratio on the GURU.Markets platform, an investor assesses the monetization efficiency of Enanta Pharmaceuticals (ENTA) antiviral therapies, including royalties from hepatitis C drugs and the potential of new developments to combat RSV and COVID-19.

Karo sapa Enanta Pharmaceuticals saingan

Koefisien rega marang pendapatan gilead.com|Multiplikator P/S CDTX (Cidara Therapeutics Inc)|Novavax Inc (NVAX) - Rega marang dodolan|CVAC - Rasio rega marang pendapatan|VALN (Valneva Vaccines) - Rasio kapitalisasi marang pendapatan|VIR: Multiplikator P/S|siga.com (SIGA) - Multiplikator P/S|Rasio rega marang pendapatan Emergent BioSolutions Inc.|Rasio kapitalisasi marang pendapatan AVIR (Atea Pharma)|Kapitalisasi marang pendapatan IVVD (Invivyd, Inc.)|Kapitalisasi marang volume dodolan INO|Multiplikator P/S HLVX (HilleVax, Inc.)|Multiplikator P/S kalaristx.com KLRS|DYAI: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan NNVC (NanoViricides, Inc.)|Talphera Corp (TLPH) - Rasio rega marang pendapatan|Rasio rega marang dodolan COCP (Cocrystal Pharma Corp)|TRAW (Traws Pharma Inc) - Multiplikator P/S|DWTX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QLGN|Multiplikator P/S allovir.com (ALVR)|Rasio rega marang pendapatan VBI Vaccines VBIV|Rasio kapitalisasi pasar marang pendapatan VIRI|VXRT - Rasio rega marang pendapatan